Verification of EZH2 as a Druggable Target in Metastatic Uveal Melanoma

Molecular Cancer - United Kingdom
doi 10.1186/s12943-020-01173-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pembrolizumab as First-Line Treatment for Metastatic Uveal Melanoma

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Is Brca-Associated Protein (Bap1) a New Drug Target to Combat Metastatic Uveal Melanoma?

Open Access Journal of Toxicology
2018English

Nestin Expression in Primary and Metastatic Uveal Melanoma - Possible Biomarker for High-Risk Uveal Melanoma

Acta Ophthalmologica
MedicineOphthalmology
2018English

YAP as Oncotarget in Uveal Melanoma

Oncoscience
Cancer ResearchOncology
2014English

iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors

PLoS ONE
Multidisciplinary
2015English

X-Linked Inhibitor of Apoptosis Protein as a Therapeutic Target in Metastatic Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2010English

Is There a Role for Immune Checkpoint Blockade in Metastatic Uveal Melanoma?

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

lncRNA SNHG7 Affects Malignant Tumor Behaviors Through Downregulation of EZH2 in Uveal Melanoma Cell Lines

Oncology Letters
Cancer ResearchOncology
2019English

EZH2 as a Therapeutic Target in Solid Tumors

Cancer Cell & Microenvironment
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy